ICD-10-CM 2027 diagnosis code
C37Malignant neoplasm of thymus
C37 is a valid, billable ICD-10-CM code for malignant neoplasm of thymus. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.
Code unchanged since ICD-10-CM took effect on October 1, 2015. Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data
About C37
C37 is the ICD-10-CM diagnosis code for malignant neoplasm of thymus. It belongs to block C30-C39 (malignant neoplasms of respiratory and intrathoracic organs) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.
Don't report C37 together with the conditions in its Excludes1 note: malignant carcinoid tumor of the thymus (C7A.091).
As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.
In MS-DRG v44.0, it is part of the grouping logic for DRG 826 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC, relative weight 4.7581), DRG 827 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC, relative weight 2.3896), DRG 828 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCC, relative weight 1.6955), DRG 829 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures with CC/MCC, relative weight 3.1281), DRG 830 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC, relative weight 1.4859), DRG 843 (Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC, relative weight 1.9453) and 2 more, in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.
Before ICD-10, this condition was coded in ICD-9-CM as 164.0 (malignant neoplasm of thymus).
Coding notes
- malignant carcinoid tumor of the thymus (C7A.091)
Notes that apply from higher levels
Instructions written at a parent level also apply to C37.
Broader instructions also apply from C30-C39 Malignant neoplasms of respiratory and intrathoracic organs and Chapter 2: Neoplasms.
Alphabetic index entries
9 entriesTerms in the official ICD-10-CM index that lead to C37.
Table of Drugs & Neoplasms entries
- Neoplasm, neoplastic › thymus (gland) — Malignant Primary
Codes whose notes reference C37
MS-DRG v44.0 grouping
All DRGs →Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.
MDC 17 · Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
- 826Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCCRW 4.7581
- 827Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CCRW 2.3896
- 828Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCCRW 1.6955
MDC 17 · Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
MDC 17 · Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
- 843Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCCRW 1.9453
- 844Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with CCRW 1.2551
- 845Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses without CC/MCCRW 0.8447
ICD-9-CM equivalent
Converter →- 164.0Malignant neoplasm of thymusexact
From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
- No changes since FY2016.
Common questions about C37
Is C37 billable?
- Yes. C37 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
Can C37 be used as a principal diagnosis?
- Yes. The Medicare Code Editor doesn't restrict C37 as a principal diagnosis.
Is C37 a CC or MCC?
- C37 is a CC (complication or comorbidity) under MS-DRG v44.0, unless excluded by the principal diagnosis.
What DRG does C37 group to?
- C37 is used in the MS-DRG v44.0 logic for MS-DRG 826 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC), MS-DRG 827 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC), MS-DRG 828 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCC), MS-DRG 829 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures with CC/MCC), MS-DRG 830 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC), MS-DRG 843 (Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC) and 2 more. Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.
What is the ICD-9 code for C37?
- The CMS General Equivalence Mappings map C37 to ICD-9-CM 164.0.